

# 'Glitches are minor, new system to work like RAC'

Many states have raised concerns over technology glitches in the vaccination delivery platform Co-WIN. **R S SHARMA**, who chairs the empowered committee on technology for Covid vaccine, spoke to Nivedita Mookerji on what went wrong with Co-Win during the first few days, the scale-up exercise, plans for a flexible system, vaccine hesitancy, and more. Edited excerpts:

## How has it been going for you as chairman of the technology platform (Co-WIN) for Covid vaccine?

I entered the system (in the newly appointed panel for Co-WIN) on January 9. I have reviewed the system and found small software glitches, which we are removing. But we have to scale up the software to cover up to 1.3 billion — which is one-sixth of humanity. Nobody has done this kind of a thing on the planet.

## What really went wrong in the first three days with Co-WIN that many states had to go manual with the vaccine tracking and delivery process?

They were minor glitches; I will give you an example. Ultimately, the vaccines are limited... You have, for instance, invited some 100 people for vaccination at a centre and perhaps only 20 turned up. For a variety of reasons, many didn't turn up. The system was designed in such a manner that if 100 were invited, they would all come and get vaccinated, and there would be another list the next day, and so on. When that didn't happen, glitches occurred.

Now we have to make the system flexible to accommodate people who have registered for today, tomorrow, and the day after... The new system will be like RAC (reservation against cancellation used widely in the railways) and people on the wait list will be accommodated for vaccination when the scheduled beneficiaries don't turn up. We didn't have that flexibility for the first few days.

## So, how do you go about making the system robust?

We have to do it in a way that's citizen-centric. That is, from vaccinating only health workers, we have to roll it out for much larger numbers in future. There's no doubt that this is the largest programme in the world. Through Co-Win, we are designing a system which is scalable and which is citizen-friendly. Self-registration will be introduced so that people can mention when and at which place they want to be vaccinated closer home. While Aadhar infrastructure will help in



**I'M RESPONSIBLE FOR MAKING A PLATFORM AND BACKBONE TO ENSURE VACCINATION'S TRACEABLE, TRANSPARENT, CITIZEN-FRIENDLY, AND THAT THERE'S NO INFORMATION ASYMMETRY.**

**R S SHARMA**

Chairman, empowered committee on technology for Covid vaccine

authenticating the process, digital certificates—provisional or final—will be given once vaccination is done.

## What else needs to be done?

We plan to eliminate any information asymmetry. Registration can be done through multiple channels including Aarogya Setu app, mobile phone, helpline or on the web. Right now, we are dealing with a captive audience—health and frontline workers. That system is scaling up and adding new components like real time dashboard and information system.

## What is the broad objective of the panel that you are chairing?

I'm responsible for making a robust technology platform and backbone to ensure vaccination is transparent, traceable, citizen-friendly and that there's no informa-

tion asymmetry. That's the broad objective and we will ensure that. Certain things are non-negotiable. For instance, real time recording of the vaccination event is very important because that's the only way we can follow up with people later on. Also, people should authenticate themselves so that there's no room for proxy. So, we are focusing on a robust authentication of system, recording of real time events and immediate issuance of certificate.

## There's very little information on the technology backend of Co-Win. Who owns it and who operates it? Are there any IT companies managing it?

We are doing it and the strategic ownership is with the government of India. Software developers may be there but the overall ownership is with the government.

## Who in the government manages it? Is it NIC (National Informatics Centre)?

I have created a group now with people from NIC and other government departments who will take ownership of Co-Win.

## You are also a member of the National Expert Group on Vaccine Administration of Covid-19. What's your assessment of the vaccine hesitancy mood in India?

There's a lot of fake news on risks and adverse effects of vaccination. That has created some fear in the minds of people. I think that's completely baseless. The initial anxiety will go away and people will go for vaccination with confidence I'm sure. That's my sense. Of course it's a subjective thing.

## Is the government doing anything to build citizen trust in vaccine?

The government is telling the truth while some people are doing campaigns against vaccines saying they are not safe, etc.

## What about the Covaxin versus Covishield debate that is going on?

This is beyond my domain (laughs). As doctors have already said, both are absolutely safe.

## Govt advises health care workers to take the jab

**RUCHIKA CHITRAVANSHI**  
New Delhi, 19 January

With more than 630,000 vaccinated within the first four days of the drive in India — the fastest in the world in doing so — the government strongly urged health care workers to shed hesitancy and come forward to take the jab in order to create a Covid-proof health care system and achieve vaccine-induced herd immunity.

"The whole world is clamouring for a vaccine. If we still decline, it would be a matter of sadness... I will urge them (health care workers) to endorse the vaccine. We have to start non-Covid services; those who are fortunate to receive the vaccine should not refuse it," said V K Paul, member (health), NITI Aayog.

Paul, who has himself taken a shot of Bharat Biotech's Covaxin, had assured people of safety. He said India has finally got a breather from Covid, and that this is the time to vaccinate as many as possible.

So far, says the health ministry, 'adverse events following immunisation' (AEFI) make up 0.18 per cent of the total vaccinations, and only 0.002 per cent cases have ended in hospitalisation.

"Concerns about adverse events following immunisation are unfounded and insignificant. We are in a situation of a lot of comfort. These two vaccines are safe. There is no undue reactivity," said Rajesh Bhushan, health secretary. According to provisional numbers, a total of 177,368 beneficiaries were vaccinated on Tuesday, across 3,800 sessions. A total of nine cases of AEFI required hospitalisation, a health ministry statement said.

The government is urging states with less than 40 per cent of the targeted coverage to take steps to ramp up the number of sessions, such as Punjab, Puducherry, and Tamil Nadu. Goa, HP, and UP hold vaccination sessions only two days a week.

# Nasal vaccine: Bharat Bio told to submit efficacy data

India may start vaccine exports as soon as today

**SOHINI DAS & RUCHIKA CHITRAVANSHI**  
19 January

The expert panel of the Central Drugs Standard Control Organisation (CDSCO) has asked Bharat Biotech to submit the efficacy data from Phase-3 trials, before it approves the application to conduct Phase-1 trial for its nasal vaccine, said sources.

Bharat Biotech had recently sought the Drugs Controller General of India's approval to conduct Phase 1 clinical trials of its nasal vaccine. For any clinical trial and vaccine approval, the CDSCO refers to the subject expert committee (SEC) for recommendations.

The SEC met on Tuesday to discuss the proposal from the vaccine maker. A source added that the panel has sought more data from the firm before it gives approval to conduct clinical trials of its

nasal vaccine. The SEC has already recommended restricted emergency-use approval for the intra-muscular vaccine developed by Bharat Biotech — Covaxin. "The SEC has sought more data from the firm, especially showing efficacy," said a source. The country also plans to export Bharat Biotech's vaccine at a later stage.

Meanwhile, in the health ministry press briefing, V K Paul, member-health, NITI Aayog, said a nasal vaccine candidate has been identified and will be considered by the regulator for Phase 1 and 2 trials. He said this route could be used to deliver safe antigen that will generate an immunological response.

Balram Bhargava, director, Indian Council of Medical Research (ICMR), said, "In the past, such vaccines have been used for measles. This is a route being explored now and we are looking forward to it."

Bharat Biotech is bullish on its upcoming nasal vaccine, which is under trials in the US. Experts say the nasal vaccine, if successful, could play a

major role in halting the transmission of the novel coronavirus and lead to global eradication of the disease.

Jacob John, former head (Centre for Advanced Research in Virology), ICMR, had told *Business Standard* recently that while intra-muscular vaccines could potentially prevent the transmission of a disease that spreads through the respiratory tract (such as the smallpox vaccine), chances were higher in case of a nasal vaccine.

Meanwhile, India — one of the world's biggest drugmakers — will start exports of Covid-19 vaccines as early as Wednesday, government sources said, paving the way for many mid- and lower-income countries to secure supplies of the easy-to-store Oxford-AstraZeneca vaccine.

The first batch of exports will be shipped to Bhutan, said officials.

Sri Lanka, Nepal, Myanmar, and the Maldives have all made requests for early delivery of vaccines.

*Additional inputs from PTI*

# Indemnity clause: Serum knocks on govt door again

**SOHINI DAS**  
Mumbai, 19 January

Amid adverse events following vaccination coming from across the country, Pune-based vaccine maker Serum Institute of India (SII) again raised the issue of indemnity in a meeting with the health ministry this week, said some-one close to the development.

SII did not wish to comment on the matter. While there are reports of adverse events, no causal link to the vaccine has been established. SII Chief Executive Officer Adar Poonawalla earlier indicated legal indemnity was required to ensure that the vaccination drive could be completed smoothly.

In an interview with *Business Standard*, Poonawalla, who is also president of the Indian Vaccine Manufacturers Association, had said an indemnity clause during the period of the pandemic would ensure the vaccination drive did not halt if there was an injunction.

"If there is an injunction and the court says that no more vaccines will be given to anyone pending further enquiry, many lives would be impacted. It is not about the financial loss to

the company. The entire government programme, too, stops. Some very high-level constitutional powers would have to be invoked to overrule such a situation. This has never been tested in our history," he had said.

Legal experts say the government is unlikely to indemnify vaccine makers. The expert panel of the Central Drugs Standard Control Organisation (CDSCO) will review the adverse events and the reports (analyses) submitted by vaccine makers. Only in case of any causal link established between any adverse event and the vaccine would the CDSCO take up the issue.

The vaccines of SII and Bharat Biotech have been approved under the New Drugs and Clinical Trial Rules, 2019, which come under the

Drugs and Cosmetics Act, 1940. In this Act, there is provision for compensation in the case of any adverse event in a trial.

SII's Covishield and Bharat Biotech's Covaxin are being given to health care workers now. Both the firms have listed on their websites adverse effects that can happen after vaccination and who should avoid taking the vaccine.

**VEE ESS FORGINGS PRIVATE LIMITED (IN LIQUIDATION)**  
E-Auction Sale Notice for sale of assets under Insolvency and Bankruptcy Code, 2016  
Details of Machineries to be e-auctioned: 1. Vertical Milling Machine, 2. Multi Spindle Drill, 3. Milling Machine, 4. Horizontal Milling Machine, 5. CNC Lathe (2 No's), 6. Air Compressor, 7. Fume Chamber, 8. Polisher, 9. Muffle Furnace, 10. Micro Scope, 11. Surface Table, 12. Hardness Testing Machine -VHN, 13. Chemical wet Analysis Apparatus, 14. Hot oven, 15. Electrical Panel, Cables & Switches, 16. Office Equipment's.  
Date and Time of Auction : 06/02/2021 - From 12.00 pm to 1.00 pm.  
Last Date for Submission of EMD and Tender Documents: 05/02/2021 (up to 4.00 pm)  
The sale will be done through public e-auction through <https://ncltauction.auctiontiger.net>  
Complete details of the Terms and conditions of E-Auction and Tender Documents are available in the website <https://www.veeessforgings.co.in> and <https://ncltauction.auctiontiger.net>  
For more information please contact : M.S.VISWANATHAN, Liquidator at [mstv8200@gmail.com](mailto:mstv8200@gmail.com) or 98840 85514.

**ASHIKA CREDIT CAPITAL LIMITED**  
CIN : L67120WB1994PLC062159  
Trinity, 226/1, A.J.C Bose Road, 7th Floor, Kolkata-700020  
Tel: (033) 40102500; Fax: (033) 40102543  
Email: [secretarial@ashikagroup.com](mailto:secretarial@ashikagroup.com); Website: [www.ashikagroup.com](http://www.ashikagroup.com)  
Pursuant to regulation 29 read with regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments thereof, Notice is hereby given that a meeting of Board of Directors of Ashika Credit Capital Ltd is scheduled to be held on Thursday, the 28th day of January, 2021, inter alia, to consider, approve and take on record the Un-Audited Financial Results of the company for the quarter and nine-months ending on 31st December, 2020 prepared in accordance with the IND-AS Rules, and any other matter with the permission of the chair.  
The said intimation is also available on the company's website at [www.ashikagroup.com](http://www.ashikagroup.com) and on websites of stock exchange at [www.bseindia.com](http://www.bseindia.com), [www.mseil.in](http://www.mseil.in) and [www.cse-india.com](http://www.cse-india.com)  
Sd/-  
(Anju Mundhra)  
Company Secretary  
FCS 6686  
Place : Kolkata  
Date : 19.01.2021

**LAURUS Labs**  
Knowledge . Innovation . Excellence  
**Laurus Labs Limited**  
CIN: L24239AP2005PLC047518  
Registered Office: Plot No.21, Jawaharalal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh  
Corporate Office: 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad - 500 034, Telangana  
Phone: +91 40 3980 4333; Fax: +91 40 3980 4320  
Email: [secretarial@lauruslabs.com](mailto:secretarial@lauruslabs.com); Website: [www.lauruslabs.com](http://www.lauruslabs.com)  
**NOTICE**  
NOTICE is hereby given, pursuant to Regulation 29 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Thursday, January 28, 2021, inter-alia, - to consider and approve the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2020; - to consider the proposal for payment of 2nd Interim Dividend for FY 2020-21 and fixation of record date for determining the eligibility of shareholders (if approved).  
Further the Notice is also available on the website of the Company at [www.lauruslabs.com](http://www.lauruslabs.com)  
By Order of the Board  
For **Laurus Labs Limited**  
Sd/- **G. Venkateswar Reddy**  
Company Secretary  
Place: Hyderabad  
Date : January 19, 2021

**WEST BENGAL STATE RURAL DEVELOPMENT AGENCY**  
(An Agency under P & RD Department)  
**GOVERNMENT OF WEST BENGAL**  
Joint Administrative Building, 6th Floor, HC-7, Sector - III  
Bidhannagar, Kolkata - 700 106  
**Press Notice**  
Chief Engineer, on behalf of WBSRDA invites online Item Rate Bids from eligible Bidders for supply, delivery and installation of equipments for the following locations in the State of West Bengal:  

Sl. No.	Location	NIB No. and Date
1.	RRNMU at Jalpaiguri	NIB No. 01/(ADB-RCIP2-TRANCHE-I)/2021(4th Call) Dated 20.01.2021
2.	RRNMU at Malda	NIB No. 02/(ADB-RCIP2-TRANCHE-1)/2021 (4th Call) Dated 20.01.2021
3.	RRNMU at Paschim Medinipur	NIB No. 03/(ADB-RCIP2-TRANCHE-I)/2021(4th Call) Dated 20.01.2021
4.	RRNMU at Purba Burdwan	NIB No. 04/(ADB-RCIP2-TRANCHE-1)/2021 (4th Call) Dated 20.01.2021

  
Date of Commencement of Downloading of Bidding Document : 21st January, 2021  
Last Date for Downloading of Bidding Document : 12th February, 2021  
Last Date and Time for Receipt of Bids Online : 12th February, 2021 @ 17.30 hrs.  
Detailed NIB and other details can be viewed on our website <http://pmsyenderswb.gov.in> from 20th January, 2021.  
Sd/-  
Chief Engineer, P & RD Department  
Block - HC 7, Sector - III, Salt Lake City, Kolkata - 700106

**Jyothy Labs**  
**JYOTHY LABS LIMITED**  
(Formerly known as Jyothy Laboratories Limited)  
CIN: L24240MH1992PLC128651  
Regd. Office: 'Ujala House', Ram Krishna Mandir Road, Kondivita, Andheri (E), Mumbai - 400 059.  
Tel: 022-66892800; Fax: 022-66892805;  
Email Id: [secretarial@jyothy.com](mailto:secretarial@jyothy.com); Website: [www.jyothy.com](http://www.jyothy.com)  
**Notice**  
Pursuant to Regulation 29 read with Regulation 47 and other relevant Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NOTICE is hereby given that a meeting of the Board of Directors of Jyothy Labs Limited (Formerly known as Jyothy Laboratories Limited) is scheduled to be held through video conferencing on Wednesday, January 27, 2021, inter-alia, to consider and approve the Unaudited Financial Results of the Company on Standalone and Consolidated basis for the quarter and nine months ended December 31, 2020, with limited review thereon by the Statutory Auditors of the Company.  
The aforesaid intimation can also be accessed on the website of the Company i.e. [www.jyothy.com](http://www.jyothy.com) and on the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).  
For **Jyothy Labs Limited**  
(Formerly known as Jyothy Laboratories Limited)  
Sd/-  
Shreyas Trivedi  
Head - Legal & Company Secretary  
Place: Mumbai  
Date : January 19, 2021

**PDS MULTINATIONAL FASHIONS LIMITED**  
CIN: L18101KA2011PLC094125  
Registered Office: #758 & 759, 2nd Floor, 19th Main, Sector-2, HSR Layout, Bengaluru 560 102, Karnataka Tel: +91 80 6765 3000  
Email: [investors@pdsinternational.com](mailto:investors@pdsinternational.com) | Website: [www.pdsinternational.com](http://www.pdsinternational.com)  
**NOTICE OF THE EXTRA-ORDINARY GENERAL MEETING OF PDS MULTINATIONAL FASHIONS LIMITED HELD THROUGH VIDEO CONFERENCING/OTHER AUDIO VISUAL MEANS**  
NOTICE is hereby given that the Extra-ordinary General Meeting ("EOGM") of PDS Multinational Fashions Limited (the "Company") will be held on Thursday, 25th day of February, 2021 at 11:00 AM (IST) through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM") to transact the business as set out in the Notice of the EOGM which is being circulated for convening the EOGM.  
In view of the continuing COVID - 19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide in its previous Circulars as well as General Circular 39/2020 dated December 31, 2020 and Securities and Exchange Board of India ("SEBI") in its Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 (collectively referred to as "Circulars") and any amendments / modifications thereof, the Companies are allowed to hold EOGM through VCO/AVM without the physical presence of Members at a common venue. Accordingly in compliance of the Circulars issued by SEBI and MCA, relevant provisions of the Companies Act, 2013 (the "Act") and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") the EOGM of the Company will be held on Thursday, 25th day of February, 2021 at 11:00 AM (IST) through VCO/AVM.  
In compliance with the above Circulars, the Notice of the EOGM will be sent to all Members in electronic mode, whose email ID's are registered with the Depository Participants / Registrar and Share Transfer Agent (RTA) of the Company.  
The Notice of the EOGM will also be made available on the Company's website at [www.pdsinternational.com](http://www.pdsinternational.com) and websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and also on the website of Linkintime India Private Limited (RTA) at [www.linkintime.co.in](http://www.linkintime.co.in).  
Members holding shares in physical mode are requested to furnish their email ID's with the Company's Registrar and Share Transfer Agent (RTA) Linkintime India Private Limited, at [enotices@linkintime.co.in](mailto:enotices@linkintime.co.in) and Members holding shares in dematerialized mode, are requested to register their email IDs with their relevant depositories through their depository participants.  
The instructions for attending the EOGM through VCO/AVM will be provided in the Notice of the EOGM.  
The Company is providing remote e-voting facility (remote e-voting) to all its Members to cast their votes on all resolutions set out in the Notice of the EOGM. Additionally, the Company will be providing the facility of voting through e-voting system during the EOGM (e-voting). Detailed procedure for remote e-voting and e-voting will be provided in the Notice of the EOGM.  
for **PDS MULTINATIONAL FASHIONS LIMITED**  
Sd/-  
Abhishek Kanoi  
Head of Legal & Company Secretary  
ICSI Membership No. FCS - 9530  
Place: Bengaluru  
Date: 19-01-2021

**Vardhman VARDHMAN SPECIAL STEELS LIMITED**  
Delivering Excellence. Since 1965.  
Regd. Office : Vardhman Premises, Chandigarh Road, Ludhiana-141010  
CIN: L27100PB2010PLC033930, PAN: AADCV4812B  
Website: [www.vardhmansteel.com](http://www.vardhmansteel.com), E-mail: [secretarial.lud@vardhman.com](mailto:secretarial.lud@vardhman.com)  
**Statement of Unaudited Financial Results for the quarter and nine month ended 31 December 2020**  
(Rs. in lakhs)  

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Unaudited)	31.12.2020 (Unaudited)	31.12.2019 (Unaudited)	
1	Total Income from Operations	29,084.13	25,267.46	18,984.70	61,314.74	64,847.63	85,559.85
2	Net Profit / (Loss) for the period before tax	3,095.36	1,506.30	(485.11)	2,650.54	(794.41)	(231.64)
3	Net Profit / (Loss) for the period after tax	2,166.80	894.01	181.01	1,783.22	(21.92)	333.99
4	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period after tax & Other Comprehensive Income]	2,154.90	868.99	176.02	1,721.28	(36.88)	249.87
5	Paid up Equity Share Capital	4,039.45	4,039.45	4,039.45	4,039.45	4,039.45	4,039.45
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						37,323.56
7	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)						
	(a) Basic	5.36	2.21	0.47	4.41	(0.06)	0.89
	(b) Diluted	5.36	2.21	0.47	4.41	(0.06)	0.89

  
Note:  
1) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the detailed Quarterly & Nine Month Ended Financial Results are available on the websites of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and also on website of the Company i.e. [www.vardhman.com](http://www.vardhman.com) and [www.vardhmansteel.com](http://www.vardhmansteel.com).  
For **Vardhman Special Steels Limited**  
Sd/-  
(Sachit Jain)  
Vice-Chairman & Managing Director  
Date : 19 January, 2021  
Place: Ludhiana